CRDL

Cardiol Therapeutics Inc

Add to Watchlist

Advanced Chart

1.096

-0.024(-2.143%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.130

Open

1.120

VWAP

1.11

Vol

241.15K

Mkt Cap

96.26M

Low

1.090

Amount

266.80K

EV/EBITDA(TTM)

Total Shares

69.00M

114.30M

EV/OCF(TTM)

P/S(TTM)

Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.110

+10%

-0.095

+5.56%

-0.095

-47.22%

Estimates Revision

The market is revising No Change the revenue expectations for Cardiol Therapeutics Inc. (CRDL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -14.34%.

EPS Estimates for FY2025

Revise Downward

-14.29%

In Past 3 Month

Stock Price

Go Down

-14.34%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast CRDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDL is 8.80 USD with a low forecast of 6.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.096

Low

6.00

Averages

8.80

High

11.00

Current: 1.096

Low

6.00

Averages

8.80

High

11.00

H.C. Wainwright

Buy

initiated

2025-06-02

Reason

H.C. Wainwright

Price Target

2025-06-02

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Cardiol Therapeutics with a Buy rating and $9 price target. Cardiol is a clinical-stage company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, the analyst tells investors in a research note. The firm says Cardiol is currently advancing CardiolRx in two lead programs that target recurrent pericarditis and acute myocarditis. It believes investors could soon come to appreciate the value to be unlocked within the company.

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-04-16

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-04-16

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-04-07

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-04-07

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-02-24

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-02-24

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2024-12-18

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2024-12-18

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2024-11-20

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2024-11-20

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cardiol Therapeutics Inc (CRDL.O) is -3.84, compared to its 5-year average forward P/E of -4.25. For a more detailed relative valuation and DCF analysis to assess Cardiol Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.25

Current PE

-3.84

Overvalued PE

-2.28

Undervalued PE

-6.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.78

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

-0.85

Undervalued EV/EBITDA

-6.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

25.13

Current PS

0.00

Overvalued PS

93.65

Undervalued PS

-43.39